Portulaca Oleracea Extract Ameliorates Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Male Sprague-Dawley Rats

Overview

Journal Vet Med Sci

Specialty Veterinary Medicine

Date 2024 Dec 31

PMID 39739367

Authors

Young-Ju Lim

Hye Rim Kim

Seul Bi Lee

Sang Back Kim

Dong-Hee Kim

Jae-Hyun So

Kyung-Ku Kang

Soo-Eun Sung

Joo-Hee Choi

MinKyoung Sung

Yeon-Ji Lee

Wook-Tae Park

Gun Woo Lee

Seul-Ki Kim

Min-Soo Seo

Affiliations

Soon will be listed here.

Abstract

Benign prostatic hyperplasia (BPH) is a distressing health problem that can cause serious complications in aging men. Androgens are implicated in the causation of BPH. Portulaca oleracea (PO) is a natural product with diverse pharmacological effects. The objective of this study was to investigate the effect of PO in a rat model of testosterone propionate (TP)-induced BPH and explore the underlying mechanisms. Thirty-five Sprague-Dawley (SD) rats were divided into the following equal groups (n = 7): normal control (NC) group, TP (3 mg/kg) group, finasteride (10 mg/kg) group, 25 and 50 mg/kg PO groups. At the end of the experiment, the body weights (BWs) of the rats were measured before they were euthanized to the establishment obtain serum and prostate weight (PW). TP-induced levels of androgen-related proteins in the prostate were also investigated. In the TP group, prostate size, BW, serum DHT level, prostate epithelial cell thickness and androgen-related protein level were higher than those in the NC group (p < 0.001). PO reversed TP-induced BPH in a dose-dependent manner (p < 0.01) and its effect was similar to that of finasteride. A similar effect of PO on the androgen-related protein level was also observed. We successfully established a TP-induced BPH rat model. This is the first study to demonstrate that inhibition of androgen-related proteins using PO can alleviate BPH.

References

Elsherbini D, Almohaimeed H, El-Sherbiny M, Mohammedsaleh Z, Elsherbiny N, Gabr S . L. Extract Attenuated Benign Prostatic Hyperplasia in Rat Model: Effect on Oxidative Stress, Apoptosis, and Proliferation. Antioxidants (Basel). 2022; 11(6). PMC: 9219805. DOI: 10.3390/antiox11061149. View

Baig M, Kolasa-Wolosiuk A, Pilutin A, Safranow K, Baranowska-Bosiacka I, Kabat-Koperska J . Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage-Animal, Experimental Study. Int J Environ Res Public Health. 2019; 16(10). PMC: 6572442. DOI: 10.3390/ijerph16101726. View

Tarter T, Vaughan Jr E . Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des. 2006; 12(7):775-83. DOI: 10.2174/138161206776056010. View

Lloyd G, Marks J, Ricke W . Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?. Curr Urol Rep. 2019; 20(9):54. PMC: 7339114. DOI: 10.1007/s11934-019-0917-1. View

Tempany C, Partin A, Zerhouni E, Zinreich S, Walsh P . The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate. 1993; 22(1):39-42. DOI: 10.1002/pros.2990220106. View

De Nunzio C, Presicce F, Tubaro A . Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016; 13(10):613-26. DOI: 10.1038/nrurol.2016.168. View

Welen K, Damber J . Androgens, aging, and prostate health. Rev Endocr Metab Disord. 2022; 23(6):1221-1231. PMC: 9789017. DOI: 10.1007/s11154-022-09730-z. View

Bespalov V, Alexandrov V, Semenov A, Tochilnikov G, Ermakova E, Zmitrichenko Y . Old Rats Are More Susceptible to Induction of Benign Prostatic Hyperplasia (BPH) at Comparative to Young Mature. Curr Aging Sci. 2021; 14(2):124-132. DOI: 10.2174/1874609814666210203091803. View

Chaudhari N, Nampoothiri L . Neurotransmitter alteration in a testosterone propionate-induced polycystic ovarian syndrome rat model. Horm Mol Biol Clin Investig. 2016; 29(2):71-77. DOI: 10.1515/hmbci-2016-0035. View

10.

Vickman R, Franco O, Moline D, Vander Griend D, Thumbikat P, Hayward S . The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian J Urol. 2020; 7(3):191-202. PMC: 7385520. DOI: 10.1016/j.ajur.2019.10.003. View

11.

Mohler J, Titus M, Bai S, Kennerley B, Lih F, Tomer K . Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011; 71(4):1486-96. PMC: 3075600. DOI: 10.1158/0008-5472.CAN-10-1343. View

12.

Jahan N, Chowdhury A, Li T, Xu K, Wei F, Wang S . Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway. Redox Rep. 2021; 26(1):1-9. PMC: 7808392. DOI: 10.1080/13510002.2021.1871814. View

13.

Csikos E, Horvath A, Acs K, Papp N, Balazs V, Dolenc M . Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021; 26(23). PMC: 8659259. DOI: 10.3390/molecules26237141. View

14.

Al-Quwaie D, Allohibi A, Aljadani M, Alghamdi A, Alharbi A, Baty R . Characterization of Whole Plant: Evaluating Antioxidant, Anticancer, Antibacterial, and Antiviral Activities and Application as Quality Enhancer in Yogurt. Molecules. 2023; 28(15). PMC: 10421184. DOI: 10.3390/molecules28155859. View

15.

Nicholson T, Ricke W . Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011; 82(4-5):184-99. PMC: 3179830. DOI: 10.1016/j.diff.2011.04.006. View

16.

Hwang E, Jung J, Borofsky M, Kim M, Dahm P . Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019; 2:CD013143. PMC: 6373984. DOI: 10.1002/14651858.CD013143.pub2. View

17.

Ganzer C, Jacobs A, Iqbal F . Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2014; 9(3):222-8. DOI: 10.1177/1557988314538445. View

18.

Jin B, Kim H, Na J, Lee W, An H . Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation. J Adv Res. 2023; 57:135-147. PMC: 10918329. DOI: 10.1016/j.jare.2023.04.006. View

19.

Chen B, Zhou H, Zhao W, Zhou W, Yuan Q, Yang G . Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in high-fat diet induced mice. Mol Biol Rep. 2012; 39(8):7981-8. DOI: 10.1007/s11033-012-1644-6. View

20.

Malek F, Boskabady M, Borushaki M, Tohidi M . Bronchodilatory effect of Portulaca oleracea in airways of asthmatic patients. J Ethnopharmacol. 2004; 93(1):57-62. DOI: 10.1016/j.jep.2004.03.015. View